Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02950220
What this trial is testing

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular Lymphoma+16 more
Kami Maddocks 2
Early research (Phase 1)Ended earlyNCT04060342
What this trial is testing

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic AdenocarcinomaEsophageal AdenocarcinomaEsophageal Squamous Cell Carcinoma+11 more
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. 61
Testing effectiveness (Phase 2)UnknownNCT05466474
What this trial is testing

PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma

Who this might be right for
Advanced Melanoma
Henan Cancer Hospital 40
Large-scale testing (Phase 3)Study completedNCT03430297
What this trial is testing

A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma

Who this might be right for
Metastatic MelanomaUnresectable Melanoma
Shanghai Junshi Bioscience Co., Ltd. 256
Testing effectiveness (Phase 2)Active Not RecruitingNCT06784648
What this trial is testing

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma MetastaticMelanoma of SkinMelanoma BRAF V600E/K Mutated+7 more
BioInvent International AB 35
Early research (Phase 1)Ended earlyNCT04116320
What this trial is testing

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Who this might be right for
MelanomaBreast CancerMerkel Cell Carcinoma+10 more
Craig L Slingluff, Jr 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT05522582
What this trial is testing

Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

Who this might be right for
Solid Tumors
Yancheng First People's Hospital 50
Testing effectiveness (Phase 2)Study completedNCT02964078
What this trial is testing

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Who this might be right for
Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute 27
Early research (Phase 1)Ended earlyNCT05069935
What this trial is testing

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Who this might be right for
Solid Tumor, Adult
Fate Therapeutics 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT06477523
What this trial is testing

Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC

Who this might be right for
SCLC, Extensive Stage
Sichuan University 57
Early research (Phase 1)UnknownNCT05008861
What this trial is testing

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Who this might be right for
Non-Small Cell Lung Cancer
Shanghai Zhongshan Hospital 20
Testing effectiveness (Phase 2)Study completedNCT02855203
What this trial is testing

Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours

Who this might be right for
Renal Cell Carcinoma
Peter MacCallum Cancer Centre, Australia 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT02717156
What this trial is testing

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

Who this might be right for
Stage IV Bladder Urothelial CarcinomaProstate CancerUrothelial Carcinoma
University of Southern California 70
Testing effectiveness (Phase 2)Study completedNCT06333769
What this trial is testing

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Who this might be right for
Mid-low Rectal Cancer
Fujian Cancer Hospital 38
Testing effectiveness (Phase 2)Study completedNCT03727880
What this trial is testing

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Who this might be right for
Resectable Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Ductal Adenocarcinoma
Lei Zheng 28
Testing effectiveness (Phase 2)Study completedNCT03255018
What this trial is testing

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Who this might be right for
Non-Hodgkin LymphomaLymphomaDiffuse Large B-Cell Lymphoma+2 more
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04995523
What this trial is testing

AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Who this might be right for
Non-Small-Cell Lung Carcinoma
AstraZeneca 212
Testing effectiveness (Phase 2)UnknownNCT04652440
What this trial is testing

Ablation Combined With PD-1 in HCC: Phase II Study

Who this might be right for
Hepatocellular Carcinoma
Sun Yat-sen University 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05524168
What this trial is testing

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Carcinoma
Sun Yat-sen University 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT05662397
What this trial is testing

HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Who this might be right for
Solid Tumor, AdultRelapsed CancerRefractory Cancer
HotSpot Therapeutics, Inc 77
Next Page